Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.39 USD | +0.63% | -3.11% | +3.23% |
Apr. 19 | Lifecore Biomedical Gets Nasdaq Warning Over Delayed Quarterly Report | MT |
Apr. 01 | Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024 | CI |
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 59% by 2026.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
Weaknesses
- Low profitability weakens the company.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+3.23% | 195M | B- | ||
+21.85% | 546B | B | ||
-4.77% | 359B | C+ | ||
+16.97% | 323B | B- | ||
+5.69% | 290B | C+ | ||
+13.68% | 234B | B+ | ||
+3.65% | 198B | B- | ||
-11.12% | 194B | A+ | ||
+8.08% | 167B | C+ | ||
-3.40% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- LFCR Stock
- Ratings Lifecore Biomedical, Inc.